We subcutaneously injected stable CTSL‐knockdown TU212 laryngeal cancer cells (shCTSL‐1, shCTSL‐2) and control cells into nude mice and monitored tumour volumes every 7 days, as shown in Figure 6A–C. The gene discussed is CTSL; the disease is laryngeal carcinoma.